We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:
A profitable animal health company with products in reproductive and osteoarthritis looking to raise capital to expand products development and markets
A company with a treatment of complex perianal fistula in patients with Crohn's disease, with orphan drug status, in a multinational Ph III clinical trial, available for licensing.
A company with novel monoclonal antibody targeting HGF, ready for Ph II, with excellent safety and indication of activity in gastric cancer, with dominant IP position, available for licensing.
An oral, Ph III, GI orphan drug opportunity, for the treatment of Familial Adenomatous Polyposis, with statistically significant positive Ph III data in a related indication, available for licensing in the US and ex EU/JP territories.
A medical device company with an approved, minimally invasive device for reconstructive and cosmetic cartilage surgery, available for sale/licensing.
A company with an immunotherapy oncology vaccine targeting WT-1, the highest NCI-rated target for onco-immunotherapy, in Ph II testing for MM and AML, available for licensing.